Online
|
|
BSE Announcements on Cadila Health
Posted by :
MMB MessengerCadila Healthcare Ltd has informed BSE regarding a Press Release dated July 27, 2009 titled "Zydus Cadila Q1 Net profit surges by 39%"...
bn market drug
Posted by : LEO THE LION
Zydus Cadila loses trademark case against Wallace
20 Jul 2009, 1930 hrs IST, Vishal Dutta, ET Bureau
Print EMail Discuss Share Save Comment Text:
AHMEDABAD: The Rs 3,000-crore Zydus Group`s listed entity Cadila Healthcare lost a trademark against Goa-based Wallace Pharmaceuticals over the
latter`s use of the brand name Mexate. In the case that came up in the Gujarat High Court, Cadila objected to Wallace`s use of its trademark. Interestingly, both the companies have registered trademark for their respective trademarks.
While Cadila has been using the brand Mexate in its drug for cancer, rheumatoid arthritis and psoriasis which they got registered as trademark in the year 1994, Wallace has been using MEXT for curing similar ailments. Both the companies have coined their brand names on the basic ingredients. While Cadila derived its name Mexate from Methotraxate, Wallace adopted the trademark MEXT, derived from Methotrexate and Folic Acid.
As per Sec. 28(3) and 30(2) of the Trade Marks Act, 1999 one registered owner cannot file a suit for infringement of trademark against another registered owner. It was on these grounds that Cadila`s plea for action of infringement did not stand.
The order observed that since in the field of medicinal preparation it is a general practice to adopt the mark from the name of the drug itself, Cadila cannot claim monopoly over the mark which is an abbreviation of a basic drug.
Wallace Pharmaceuticals argued that it had applied for the mark as early as in 2002, and Cadila did not raise objection then. Subsequently, Wallace grew its brand and build a market for the product, besides regularly publishing its trademark in various medicinal journals and other magazines as well.
Wallace also supported its claim by producing sales figures from the year 2003 to 2007, which established the extensive use of trademark.
Source:ET...
NSE Announcements on Cadila Health
Posted by : MMB MessengerCadila Healthcare Limited has informed the Exchange that the Company shall make the payment of dividend on equity shares of the Company on or after August 04, 2009 as may be approved by the members at the Annual General Meeting of the Company to be held on July 29, 2009. Further, the Board of Directors has recommended dividend of Rs. 4.50 (90%) per equity share of the face value of Rs.5/- each....
NSE Announcements on Cadila Health
Posted by : MMB MessengerCadila Healthcare Limited has informed the Exchange regarding a press release dated July 13, 2009, titled "Zydus Cadila and Karo Bios research collaboration has generated promising lead compounds". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). ...
BSE Announcements on Cadila Health
Posted by : MMB MessengerCadila Healthcare Ltd has informed BSE regarding a Press Release dated July 13, 2009 titled "Zydus Cadila and Karo Bios research collaboration has generated promising lead compounds"...
BSE Announcements on Cadila Health
Posted by : MMB MessengerCadila Healthcare Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on July 27, 2009, inter alia, to consider unaudited financial results for the quarter ended June 30, 2009 (Q1)....
J V to introduce Swine flu vaccine
Posted by : rvk41
Cadila Pharmaceuticals Ltd announced a joint venture with US-based vaccine company Novavax Inc to, among other things, introduce in India a vaccine against swine flu.
The joint venture - CPL Biologicals Pvt Ltd - will be started with an initial investment of Rs 100 crore and will try to bring the vaccine, which is at an advanced stage of development in the US, to India in 2009-10.
Looking at the global spread of swine flu and the WHO declaring the flu a pandemic (H1N1 influenza), the joint venture could potentially market some 50 million doses of the vaccine annually in India.
At Rs 1,000 a shot, the market size could be Rs 5,000 crore in the country, said Rahul Singhvi, President and CEO, Novavax.
The joint venture of Cadila (80 per cent) and Novavax (20 per cent) was formed according to the agreement signed between the two companies in March. CPL Biologicals will work for development and manufacturing of therapeutic and prophylactic vaccines, biological therapeutics and diagnostics, the CPL Chairman, Indravadan A. Modi, told a press conference.
Besides swine flu vaccine, the joint venture would also work on the development of "novel, affordable vaccines" to prevent avian flu, cancer, SARS, chikungunya and more such diseases.
The Chairman of Novavax, John Lambert, and the Vice-President (Strategy), Thomas J. Johnston, were also present at the event.
Cadila Pharma is the largest shareholder of Novavax, a Nasdaq-listed, clinical stage biotechnology company, and has a position on the Novavax board.
Introducing Novavax`s "virus-like particles" (VLP) technology, that compresses vaccine manufacturing time and mimics the virus without the ability to cause infection, the joint venture intends to launch the swine flu vaccine soon, provided it receives approvals, as it was under phase-II clinical trials in the USA.
The vaccine would be first procured from Novavax before being manufactured in India, at the Dholka facility of Cadila Pharma.
For information,with regards
rvk41...
ANY IDEA OF PRICE
Posted by : LEO THE LION
its a mkt sentiment.........
but will be safe........downside much limited.
300 is a strong support...
ANY IDEA OF PRICE
Posted by :
chintan voraDO anyone from us have any idea, why the share price is moving down? Every day 5 - 10 rupees down.... Pleae let me know the excat thing related to this script and any idea on price......
TB treatment cost reduced by 33%
Posted by : 06mph010
dear rvk41,
for yr kind information that text which u had written is abt cadila pharmaceuticals.
And this is cadila healthcare.Both company are totally different and there is no reletion of any type beetwin this two company.
Regards...
TB treatment cost reduced by 33%
Posted by : rvk41
Nearly three months after unveiling its potential blockbuster cardiac drug – Polycap, Ahmedabad-based Rs 800-crore Cadila Pharmaceuticals will soon come out with yet another promising drug that can bring down the cost for TB treatment by 33%.
The drug would hit the market over the next two weeks and promises to slash public healthcare costs significantly.
"The new drug, called Resorine, has been developed as a bio-enhancer that reduces the dosage of the existing drug administered to the tuberculosis patients, yet maintains the efficacy," Cadila chairman IA Modi told ET.
He further said that due to ‘Resorine’ the cost of tuberculosis treatment would get reduced by 30–33%, which according to him, will help developing countries like India that have a vast TB population. The company has completed phase III clinical trial over Resorine and also got USFDA’s approved protocol.
For information,with regards
rvk41...
bn market drug
Posted by : LEO THE LION
Cadila promises to cut TB costs by 33% in yet another breakthrough
25 Jun 2009, 1756 hrs IST, Vishal Dutta, ET Bureau
AHMEDABAD: Nearly three months after unveiling its potential blockbuster cardiac drug – Polycap, Ahmedabad-based Rs 800-crore Cadila Pharmaceuticals
will soon come out with yet another promising drug that can bring down the cost for TB treatment by 33%. The drug would hit the market over the next two weeks and promises to slash public healthcare costs significantly.
"The new drug, called Resorine, has been developed as a bio-enhancer that reduces the dosage of the existing drug administered to the tuberculosis patients, yet maintains the efficacy," Cadila chairman IA Modi told ET.
He further said that due to ‘Resorine’ the cost of tuberculosis treatment would get reduced by 30–33%, which according to him, will help developing countries like India that have a vast TB population. The company has completed phase III clinical trial over Resorine and also got USFDA’s approved protocol.
In a recent report, World Health Organisation (March 2008) says TB is a major cause of many illnesses and deaths worldwide. Globally, there were 92 lakh new cases and 17 lakh died due to TB in 2006. India alone is home to over 34 lakh tuberculosis patients and 3.25 lakh people in India died due to TB in 2005. As per WHO estimates, TB treatment costs run up to $3 billion every year.
Among the two keys drugs that go into the treatment of TB, Refampicin, is the costliest drug and needs to be administered in 450 ml dosage per day to the patient. Cadila that carried out bio-enhancement (altering the bio-ability) in its new drug has reduced the dosage of the Refampicin from 450 ml to up to 200 ml. Thus, by reducing the volume of the costlier drug in its new offering, the company has cut down on the costs. In the process, the company also claimed to have almost eliminated side-effects like liver toxicity, jaundice, flu-like-syndrome, vomiting and diarrohea.
Dr Naresh Patel, head of department of TB & chest diseases at Smt. NHL Municipal Medical College, Ahmedabad, told ET: "Resorine’s major advantage is that it enhances one of the key drugs that are used in the treatment of TB." Dr Patel is a pulmonology consultant who contributed to the research for Resorine.
Seeing a huge business potential, Cadila Pharma has already began production of Resorine and expects governments, the world over, to choose the new drug for bringing down healthcare cost around TB treatment.
It may be recalled that Cadila Pharma in March introduced Polycab, a 5-in-1 cardiac pill aimed at healthy people who are prone to heart ailment. Such a section of people includes smokers, diabetic, hypertensive and those with high levels of cholesterol. The drug was hailed by the international medical community as a major breakthrough and the research made it to renowned medical journal Lancet. The Ahmedabad-based major will commercially launch Polycap very soon.
...
bn market drug
Posted by : tara23yes happy days are here again to you and your stocks...
bn market drug
Posted by : LEO THE LIONsolid close at 370.............
bn market drug
Posted by : LEO THE LIONok.......................
